The U.S. Food and Drug Administration granted accelerated approval to Gilead Company Kite’s Tecartus (brexucabtagene autoleucel, formerly KTE-X19) as the first approved chimeric antigen receptor T cell therapy for the treatment of adult patients with relapsed or refractory mantle cell lymphoma.

Astellas Pharma Inc. bought U.S.-based Xyphos Biosciences Inc. to expand the Japanese drugmaker’s immuno-oncology business, a deal worth up to $665 million.